De novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme Plasmepsin II

ChemBioChem

Volumn 3, Issue 11, 2002, Pages 1137-1141

  Carcache, David A ^a   Hörtner, Simone R ^a   Bertogg, Andreas ^a   Binkert, Christoph ^b   Bur, Daniel ^b   Peter Märki, Hans ^c   Dorn, Arnulf ^c   Diederich, François ^a  

^a ETH ZURICH   (Switzerland)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

De novo design; Enzymes; Inhibitors; Malaria; Structure activity relationships

Indexed keywords

ANTIMALARIAL AGENT; ENZYME INHIBITOR; PLASMEPSIN II;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; MALARIA; MOLECULAR MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; ASPARTIC ENDOPEPTIDASES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP;

PLASMODIUM FALCIPARUM;

EID: 0037021351     PISSN: 14394227     EISSN: None     Source Type: Journal    
DOI: 10.1002/1439-7633(20021104)3:11<1137::AID-CBIC1137>3.0.CO;2-A     Document Type: Article

References (26)

1. U. Weiss, Nature 2002, 415, 669.
2. R. G. Ridley, Nature 2002, 415, 686-693.
3. A. M. Silva, A. Y. Lee, S. V. Gulnik, P. Majer, J. Collins, T. N. Bhat, P. J. Collins, R. E. Cachau, K. E. Luker, I. Y. Gluzman, S. E. Francis, A. Oksman, D. E. Goldberg, J. W. Erickson, Proc. Natl. Acad. Sci. USA 1996, 93, 10034-10039.
4. For peptidic and peptidomimetic inhibitors of plasmepsins, see: a) C. D. Carroll, H. Patel, T. O. Johnson, T. Guo, M. Orlowski, Z.-M. He, C. L. Cavallaro, J. Guo, A. Oksman, I. Y. Gluzman, J. Connelly, D. Chelsky, D. E. Goldberg, R. E. Dolle, Bioorg. Med. Chem. Lett. 1998, 8, 2315-2320; b) T. S. Haque, A. G. Skillman, C. E. Lee, H. Habashita, I. Y. Gluzman, T. J. A. Ewing, D. E. Goldberg, I. D. Kuntz, J. A. Ellman, J. Med. Chem. 1999, 42, 1428-1440; c) S. Jiang, S. T. Prigge, L. Wei, Y.-E. Gao, T. H. Hudson, L. Gerena, J. B. Dame, D. E. Kyle, Antimicrob. Agents Chemother. 2001, 45, 2577-2584.
5. For peptidic and peptidomimetic inhibitors of plasmepsins, see: a) C. D. Carroll, H. Patel, T. O. Johnson, T. Guo, M. Orlowski, Z.-M. He, C. L. Cavallaro, J. Guo, A. Oksman, I. Y. Gluzman, J. Connelly, D. Chelsky, D. E. Goldberg, R. E. Dolle, Bioorg. Med. Chem. Lett. 1998, 8, 2315-2320; b) T. S. Haque, A. G. Skillman, C. E. Lee, H. Habashita, I. Y. Gluzman, T. J. A. Ewing, D. E. Goldberg, I. D. Kuntz, J. A. Ellman, J. Med. Chem. 1999, 42, 1428-1440; c) S. Jiang, S. T. Prigge, L. Wei, Y.-E. Gao, T. H. Hudson, L. Gerena, J. B. Dame, D. E. Kyle, Antimicrob. Agents Chemother. 2001, 45, 2577-2584.
6. For peptidic and peptidomimetic inhibitors of plasmepsins, see: a) C. D. Carroll, H. Patel, T. O. Johnson, T. Guo, M. Orlowski, Z.-M. He, C. L. Cavallaro, J. Guo, A. Oksman, I. Y. Gluzman, J. Connelly, D. Chelsky, D. E. Goldberg, R. E. Dolle, Bioorg. Med. Chem. Lett. 1998, 8, 2315-2320; b) T. S. Haque, A. G. Skillman, C. E. Lee, H. Habashita, I. Y. Gluzman, T. J. A. Ewing, D. E. Goldberg, I. D. Kuntz, J. A. Ellman, J. Med. Chem. 1999, 42, 1428-1440; c) S. Jiang, S. T. Prigge, L. Wei, Y.-E. Gao, T. H. Hudson, L. Gerena, J. B. Dame, D. E. Kyle, Antimicrob. Agents Chemother. 2001, 45, 2577-2584.
7. G. H. Coombs, D. E. Goldberg, M. Klemba, C. Berry, J. Kay, J. C. Mottram, Trends Parasitol. 2001, 17, 532-537.
8. a) U. Obst, V. Gramlich, F. Diederich, L. Weber, D. W. Banner, Angew. Chem. 1995, 107, 1874-1877; Angew. Chem. Int. Ed. Engl. 1995, 34, 1739-1742;
9. a) U. Obst, V. Gramlich, F. Diederich, L. Weber, D. W. Banner, Angew. Chem. 1995, 107, 1874-1877; Angew. Chem. Int. Ed. Engl. 1995, 34, 1739-1742;
10. b) U. Obst, R. Betschmann, C. Lerner, R. Seiler, F. Diederich, V. Gramlich, L. Weber, D. W. Banner, P. Schönholzer, Helv. Chim. Acta 2000, 83, 855-909;
11. c) P. Betschmann, S. Sahli, F. Diederich, Helv. Chim. Acta 2002, 85, 1210-1245.
12. a) B. Masjost, R. Ballmer, E. Borroni, G. Zürcher, F. K. Winkler, R. Jakob-Roetne, F. Diederich, Chem. Eur. J. 2000, 6, 971-982;
13. b) C. Lerner, A. Ruf, V. Gramlich, B. Masjost, G. Zürcher, R. Jakob-Roetne, E. Borroni, F. Diederich, Angew. Chem. 2001, 113, 4164-4166; Angew. Chem. Int. Ed. 2001, 40, 4040-4042.
14. b) C. Lerner, A. Ruf, V. Gramlich, B. Masjost, G. Zürcher, R. Jakob-Roetne, E. Borroni, F. Diederich, Angew. Chem. 2001, 113, 4164-4166; Angew. Chem. Int. Ed. 2001, 40, 4040-4042.
15. E. A. Meyer, R. Brenk, R. K. Castellano, M. Furler, G. Klebe, F. Diederich, ChemBioChem 2002, 3, 250-253.
16. C. Oefner, A. Bingeli, V. Breu, D. Bur, J.-R. Clozel, A. D'Arcy, A. Dorn, W. Fischli, F. Grüninger, R. Güller, G. Hirth, H.-P. Maerki, S. Matthews, M. Müller, R. G. Ridley, H. Stadler, E. Vieira, M. Wilhelm, F. K. Winkler, W. Wostl, Chem. Biol. 1999, 6, 127-131.
17. For a broader application of 3,4-disubstituted piperidine inhibitors of the aspartic proteases renin and pepsin, which undergo in both cases a conformational change of the flap atop the catalytic site, see; a) M. G. Bursavich, C. W. West, D. H. Rich, Org. Lett. 2001, 3, 2317-2320; b) M. Bursavich, D. H. Rich, Org. Lett. 2001, 3, 2625-2628.
18. For a broader application of 3,4-disubstituted piperidine inhibitors of the aspartic proteases renin and pepsin, which undergo in both cases a conformational change of the flap atop the catalytic site, see; a) M. G. Bursavich, C. W. West, D. H. Rich, Org. Lett. 2001, 3, 2317-2320; b) M. Bursavich, D. H. Rich, Org. Lett. 2001, 3, 2625-2628.
19. N. K. Bernstein, M. M. Cherney, H. Loetscher, R. G. Ridley, M. N. G. James, Nat. Struct. Biol. 1999, 6, 32-37.
20. P. R. Gerber, K. Müller, J. Comput.-Aided. Mol. Des. 1995, 9, 251-268.
21. L. Grehn, U. Ragnarsson, Angew. Chem. 1984, 96, 291-292; Angew. Chem. Int. Ed. Engl. 1984, 23, 300-301.
22. L. Grehn, U. Ragnarsson, Angew. Chem. 1984, 96, 291-292; Angew. Chem. Int. Ed. Engl. 1984, 23, 300-301.
23. M. Hu, N. Brasseur, S. Z. Yildiz, J. E. v. Lier, C. C. Leznoff, J. Med. Chem. 1998, 41, 1789-1802.
24. 13C NMR and IR spectroscopies, MS, and elemental analysis or high-resolution MS.
25. K. Sonogashira in Metal-catalyzed Cross-coupling Reactions (Eds.: F. Diederich, P. J. Stang), Wiley-VCH, Weinheim, 1998, pp. 203-230.
26. 50 values for some of the inhibitors were also determined by a second method, not reported here; good agreement between the data was found.